After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Kura Oncology Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Kura Oncology Inc is $1.35B. A total of 1.65 million shares were traded on the day, compared to an average of 1.39M shares.
In the most recent transaction, DALE STEPHEN sold 4,825 shares of KURA for 21.55 per share on Jan 30 ’24. After the transaction, the Chief Medical Officer now owns 38,817 company shares. In a previous transaction on Jan 29 ’24, DALE STEPHEN sold 7,158 shares at 17.80 per share. KURA shares that Chief Medical Officer owns now total 43,642.
Among the insiders who sold shares, DOYLE THOMAS JAMES disposed of 2,318 shares on Jan 29 ’24 at a per-share price of $17.80. This resulted in the SVP, Finance & Accounting holding 48,093 shares of KURA after the transaction. In another insider transaction, Bair Teresa Brophy sold 2,053 shares at $17.80 per share on Jan 29 ’24. Company shares held by the Chief Legal Officer now total 68,979.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, KURA has a high of $24.17 and a low of $7.41.
As of this writing, KURA has an earnings estimate of $Kintara Therapeutics, Inc. per share for the current quarter. EPS was calculated based on a consensus of Global X Uranium ETF estimates, with a high estimate of $Zura Bio Limited per share and a lower estimate of $Kura Oncology, Inc..
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. KURA’s latest balance sheet shows that the firm has $517.96M in Cash & Short Term Investments as of fiscal 2021. There were $6.88M in debt and $22.45M in liabilities at the time. Its Book Value Per Share was $5.34, while its Total Shareholder’s Equity was $506.61M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for KURA is Buy with a score of 4.86.
